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Abstract 
Introduction 
Obesity is associated with inflammation, which contributes to several obesity-related 
comorbidities. This inflammation is characterized by increased inflammatory cytokine 
expression in adipose tissue (AT) depots and the liver. Dietary restriction of the essential 
amino acid methionine, in rodents, has been shown to improve body weight and 
adiposity, decrease high-fat diet- and age-induced inflammation, reduce hepatic steatosis, 
and increase insulin sensitivity despite inducing hyperphagia. Recent studies indicate that 
dietary methionine restriction (MR) rapidly and persistently increases tissue and 
circulating concentrations of the hormone fibroblast growth factor 21 (FGF21). In 
rodents, FGF21 has been shown to reduce body weight, increase insulin sensitivity, and 
recent reports indicate it may also decrease inflammation. STAT3 is a generally pro-
inflammatory transcription factor which microarray analyses have identified as a 
potential “master regulator” of inflammatory processes in MR. We hypothesized that MR 
decreases inflammation by increasing FGF21 and downregulating STAT3 signaling. 
Methods 
24 wild type (WT) C57BL/6J and 24 Fgf21 knock-out (KO) mice were fed a high-fat diet 
for four weeks, then randomized to a high-fat control (CON) diet or high-fat MR diet for 
13 weeks. RT-PCR was used to measure markers of inflammation in the liver and 
epididymal white adipose tissue (EWAT). Western blot analyses were conducted to 
determine whether STAT3 activity was affected by MR. 
Results 
  
Fgf21KO mice had elevated hepatic expression of Ccl2 (MCP-1), and MR significantly 
decreased its expression in Fgf21KO, but not WT mice.  In EWAT, Fgf21KO mice had 
elevated expression of Emr1 (F4/80), and MR reduced its expression in Fgf21KO mice, 
but not WT mice.  MR reduced Ccl2 expression in EWAT of both genotypes. Expression 
levels of Itgam (CD11b) and IL-6 in EWAT did not differ amongst groups. MR decreased 
STAT3 phosphorylation at Tyr705 in both genotypes, but had no effect on Ser727 
phosphorylation.   
Conclusion 
The RT-PCR results suggest that mice lacking FGF21 may be more susceptible to HFD-
induced inflammation. Since MR induced comparable reductions in inflammatory 
markers in both genotypes, at first glance it appears that FGF21 does not play a role in 
the mechanism by which MR decreases inflammation. However, it should be noted that 
in Fgf21KO mice, MR induced an unexpected decrease in food intake that resulted in 
reduced body weight and adiposity compared to control-fed Fgf21KO mice. Western blot 
results support the hypothesis that MR decreases inflammation by downregulating 
STAT3 signaling.
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Chapter I 
Introduction 
 The prevalence of obesity is on the rise in the US and is contributing to increased 
healthcare costs and the declining health of those with obesity. Obesity is associated with 
inflammation, which contributes to several obesity-related comorbidities. This 
inflammation is characterized by increased inflammatory cytokine expression in adipose 
tissue (AT) depots and the liver. Inflammatory markers often upregulated by obesity 
include MCP-1, IL-1β, TNF-α, IFN-γ, F4/80, ITGAM, and ITGAX.  
 Given the increasing prevalence of obesity, a common goal of researchers is to 
identify effective and safe methods for preventing or reversing obesity and metabolic 
disease. Dietary restriction of the essential amino acid, methionine, presents as an 
intriguing treatment for obesity and its comorbidities. Methionine restriction (MR) has 
been shown to improve several signs of metabolic health in rodents. MR reduces body 
weight and adiposity, decreases high-fat diet- and age-induced inflammation, reduces 
hepatic steatosis, and increases insulin sensitivity. All of these beneficial effects of MR 
occur despite an increase in energy intake. 
Recent studies indicate that dietary MR rapidly and persistently increases tissue 
and circulating concentrations of the hormone fibroblast growth factor 21 (FGF21). 
FGF21 increases insulin sensitivity, reduces body weight, and has been shown to 
downregulate markers of inflammation in white adipose tissue (WAT) of obese mice and 
spleen of arthritic mice. This hormone is considered anti-obesogenic, however serum 
levels are increased in obesity, suggesting an FGF21-resistant state. Little is known about 
the role of FGF21 in inflammation, though recent studies show that treatment with the 
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inflammatory cytokine TNF-α reduces FGF21 signaling in adipocytes. Additionally, 
FGF21 was shown to reduce inflammatory cytokine expression in WAT of obese mice 
and in the spleen of arthritic mice. 
 STAT3, a generally pro-inflammatory transcription factor, is activated by JAK-
mediated phosphorylation, which allows it to translocate to the nucleus and affect 
transcription, propagating the inflammatory response. Microarray analyses suggested that 
STAT3 signaling is downregulated by MR in liver and WAT, identifying STAT3 as a 
potential mediator of the anti-inflammatory effects of MR. 
 The purpose of the current study was to determine whether FGF21 mediates the 
anti-inflammatory effects of MR and to identify whether downregulation of STAT3 
signaling is involved. Gene expression of inflammatory markers and phosphorylation of 
STAT3 was measured in AT and liver samples from wild-type (WT) and Fgf21 knockout 
(KO) mice. 
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Chapter II 
Literature Review 
Obesity-Induced Inflammation 
 Obesity is associated with chronic, low-grade, systemic inflammation.1 Obesity-
induced inflammation is similar to aging-related inflammation.2 Both aging-related 
inflammation and obesity-associated inflammation are characterized by increased 
inflammatory cytokine expression and production of reactive oxygen species (ROS).2,3 
The inflammatory cytokines produced by obesity are found in circulation, characterizing 
the chronic inflammation as “systemic,” and the inflammation is not associated with 
infection, characterizing it as “low-grade”.1 Though systemic, the inflammation is 
especially increased in adipose and liver tissues.4  Cytokines produced in the AT as a 
result of obesity include IL-1β, IL-6, and TNF-α, which are thought to be regulated by 
the transcription factor NF-κB.5-9  
 Macrophages, cells involved in the body’s immune responses, also play an 
important role in obesity-induced inflammation.10 Polarization of macrophages influences 
their functions, with M1 polarization leading to phagocytosis of dead adipocytes and M2 
polarization producing anti-inflammatory cytokines.11,12 Obesity induces polarization 
toward the M1 (inflammatory) type, further contributing to an increase in production of 
pro-inflammatory cytokines.10 Similarly to adipose tissue, the liver also experiences 
increased inflammation in the presence of obesity.4 Kupffer cells, immune cells similar to 
macrophages but specific to the liver, will release cytokines, aiding in the development of 
inflammation.4,13 
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 A high fat diet (HFD) is traditionally used to induce obesity and related 
inflammation in rodents.14 In a study where a HFD and a normal fat diet (NFD) were fed, 
for 12 weeks, to mice and compared, the HFD-fed mice weighed more than the NFD-fed 
mice, despite similar calorie consumption.14 The HFD also triggered inflammation, 
shown by increases in white adipose tissue (WAT) expression of F4/80, Cd11b, Cd11c, 
MCP-1, and TNF-α.14 
 
Obesity-Related Comorbidities 
 Obesity can lead to a slew of health problems, including type 2 diabetes mellitus 
(T2DM), hypertension (HTN), dyslipidemia, hepatic steatosis, and cardiovascular disease 
(CVD).1 Inflammation has been linked to the development and progression of insulin 
resistance, which can result in the development of T2DM.1,15 Due to the increased 
prevalence of obesity, it is especially important to find safe and effective ways to combat 
excess adiposity, inflammation, and the comorbidities associated with obesity. 
 Obesity often leads to the development of T2DM, especially in those genetically 
prone to the disease. Obesity increases insulin resistance via inflammation. Specifically, 
pro-inflammatory cytokine release (TNF-α, IL-6 and MCP-1), amongst other pro-
inflammatory factors from macrophages and AT, likely contribute to insulin resistance.16-
18 Insulin resistance causes increased production of insulin by pancreatic β cells. Insulin 
resistance leads to the development of T2DM when pancreatic β cells can no longer meet 
insulin production needs.16,19,20 
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 CVD is linked to both systemic inflammation and obesity, independently.21-23 As 
discussed previously, obesity leads to systemic inflammation. It is believed that this 
systemic inflammation is a risk factor for CVD.21 Systemic inflammation likely causes or 
contributes to atherosclerosis.21 Atherosclerosis causes arteries to narrow, which can 
contribute to development of HTN. Obesity can cause CVD through the development of 
atherosclerosis. Additionally, dyslipidemia, insulin resistance, and T2DM – all associated 
with obesity – can contribute to CVD.21,24 
 
Dietary Methionine Restriction 
 In 1935 a group of scientists demonstrated that calorie restriction (CR) to 60% ad 
libitum intake could increase life span in rats.25 In addition, this new dietary approach 
resulted in smaller sizes and body weights in the rats.25 Though this research is over 80 
years old, it is still relevant today. More recent studies have shown that CR produces life-
span extension effects (30-40%) in multiple species.2,26 However, it is not thought to be 
ideal for human applications because of the difficulty in adhering to such a restrictive 
diet.2 In hopes of finding a diet that would work for humans and produce similar effects 
as CR, researchers searched for components of CR that lead to the enhanced longevity 
and decreased body mass benefits. While restriction of carbohydrates and fats did not 
seem to produce similar effects to CR, protein restriction did cause life-span extension, 
though not to the same degree as CR. Therefore, research continued into the restriction of 
various amino acids. In 1993, the restriction of the essential amino acid methionine was 
found to produce health benefits similar to those of CR in rats. It was discovered that an 
80% reduction of methionine (by weight) in the diet resulted in 30% longer life span and 
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smaller body size and weight in rats.27 Additionally, it appeared as though this diet may 
be more feasible for human application because, when fed ad libitum, energy intake 
actually increased in methionine-restricted animals.27 
 Since 1993, more benefits of dietary methionine restriction (MR) have been 
uncovered. Reduction in adiposity, especially in the visceral adipose tissue (VAT) depot, 
caused by MR has been seen in multiple studies,27-30 which is likely a major contributor 
to lowered risk of developing obesity-associated co-morbidities. In fact, surgical removal 
of VAT in rats has been shown to increase insulin sensitivity,31 delay diabetes onset,32 
and increase mean and maximal life span33 despite similar amounts of total fat when 
compared to control groups whom had not had VAT surgically removed.33 MR also 
increases insulin sensitivity.28,30,34 Decreased pro-inflammatory marker expression in 
peripheral tissues as a result of MR15 could be an effect of decreased adiposity and a 
cause of increased insulin sensitivity. 
 MR reduces hepatic lipid stores, reducing the risk of hepatic steatosis often seen 
with obesity,28,35 and reduces serum lipid levels.29 The reduction in hepatic lipid stores 
are due to changes in lipid metabolism. In a study on male F344 rats, MR caused an 
increase in hepatic fatty acid oxidation and a simultaneous decrease in hepatic fatty acid 
synthesis.28  
 The anti-obesogenic hormone, fibroblast growth factor-21 (FGF21), is increased 
by MR.28,36-38 FGF21 has been shown to increase glucose uptake by adipocytes, 
independent of insulin activity, prevent obesity, and decrease blood glucose and 
triglyceride levels.39  
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 What makes MR an especially unique dietary approach is its ability to increase 
energy expenditure (EE)27,28,35,37 and induce a hyperphagic response.28,29,37 Additionally, 
enhanced metabolic flexibility, shown by increased ranges in respiratory exchange ratio 
(RER), has been observed in rats.28,37 
 Plaisance et al. conducted a human study to investigate the effects of MR, 
implemented for 16 weeks, in adults with metabolic syndrome.35 All participants 
consumed methionine-restricted shakes, unlimited fruits and vegetables (which contain 
very little methionine), and some grains (which also do not contain a lot of methionine) 
for the entire study. During that time, the control group received methionine supplements 
and the MR group received placebo capsules. At the conclusion of the study, the control 
and MR groups had comparable reductions in body weight, which caused improved 
biomarkers (fasting insulin, plasma adiponectin, plasma TG, FFA, total cholesterol, etc.) 
in participants from both groups. That the control group and the MR group both lost 
weight could be viewed as a weakness of the study, since it made it difficult to 
distinguish the effects of dietary MR. Two effects were unique to MR: 1) subjects fed the 
MR diet had significantly less lipid storage compared to the control group, and 2) 
subjects in the MR group oxidized more fat, as indicated by lower RQ values. Despite 
some promising results, the study design contained a major flaw. While methionine was 
restricted, the shakes contained cysteine, a metabolic product of methionine, which 
caused diminished efficacy of the restriction of methionine in the shakes. Studies have 
shown that when cysteine is added back to the MR diet, many of the beneficial effects of 
MR are reversed.40 Cysteine addition to the MR diet in rodents ameliorated the ability of 
MR to decrease body weight, adiposity, and serum triglycerides.40 Future clinical studies 
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must eliminate cysteine in addition to restricting methionine in order to collect non-
confounded results.35 
 The multitude of benefits provided by this diet, in addition to the fact that it does 
not restrict food portions or calories, makes it a contender for human applications, 
specifically in populations suffering from metabolic syndrome and other obesity-
associated morbidities. Additionally, further investigation into the mechanisms mediating 
the beneficial effects of MR could yield potential therapeutic strategies to treat obesity 
and related complications. 
 
Anti-Inflammatory Effects of MR 
 MR induces anti-inflammatory actions in both liver and WAT.15 These anti-
inflammatory effects seem to not be a direct effect of decreased adiposity but, rather, 
from metabolic changes.15 Using quantitative RT-PCR to measure expression of pro-
inflammatory genes, Wanders et al. described transcriptional anti-inflammatory effects of 
MR in rats fed either MR or a control diet for 20 months. In retroperitoneal white adipose 
tissue (RPWAT), expression levels of Ccl2 (MCP-1), Il1b, Tnf, Ifng, Emr1 (F4/80), 
Itgam, and Itgax were decreased in rats fed the MR diet. In inguinal white adipose tissue 
(IWAT) MR reduced Ccl2 (MCP1) expression by 2.9-fold. Epidydimal white adipose 
tissue (EWAT) analysis showed downregulation of Emr1, Itgam,and Itgax mRNA 
expression. Finally, hepatic expression of Ccl2, Il1b, Tnf, Ifng, Emr1, Itgam, and Itgax 
were reduced by MR. In addition to MR, a CR diet was assessed in the same study. 
 9 
 
Results indicated that MR caused greater downregulation of inflammatory genes than CR 
in both liver and AT.15 
 
Fibroblast Growth Factor 21 (FGF21) 
 FGF21 is a hormone secreted primarily by the liver, but also by AT.41,42 In these 
organs, it works to regulate glucose and lipid metabolism and homeostasis.41-44 Through 
PPARα-mediated activation, FGF21 binds to an FGF receptor with help from co-receptor 
βKlotho. Binding to the FGF receptor causes it to dimerize, autophosphorylate, and 
activate a signaling cascade. The signaling cascade causes the activation of extracellular 
mitogen-activated protein kinase 1 & 2 (ERK1/2), which allows it to activate several 
transcription factors.43 FGF21 regulates glucose metabolism potentially through this 
mechanism. By upregulating GLUT1 expression in AT, glucose uptake is increased, 
independent of insulin action.42,43,45 
 Although FGF21 is considered anti-obesogenic, serum levels tend to be elevated 
in both obese mice and humans. Many scientists have proposed the idea of “FGF21-
resistance,” a concept similar to that of insulin-resistance, where the body is desensitized 
to the hormone and, therefore, increases its production with little benefit.41-43,45 Scientists 
seem to agree that FGF21 resistance is a result, not the cause of obesity.43,45 Despite 
resistance to the hormone, exogenous administration of FGF21 to obese rodents has 
shown improvements in weight with little to no side effects,44 making administration of 
FGF21 a potential pharmacological therapy for obesity. 
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 In addition to its work in improving glucose and lipid metabolism and 
homeostasis, FGF21 is associated with reduced inflammation. Treatment of adipocytes 
with TNF-α decreased FGF21 signaling by reducing the expression of its essential co-
receptor βKlotho.46 In addition to being affected by inflammation, FGF21 also reduces 
inflammation. A study using recombinant FGF21 showed that FGF21 reduced 
inflammatory cytokines IL-6 and TNF-α in WAT of rats with monosodium glutamate-
induced obesity.47 In arthritic mice, exogenous FGF21 administration caused 
downregulation of several pro-inflammatory cytokines in the spleen, including TNF-α, 
IL-1β, and IL-6.48,49 Research on the role FGF21 plays in inflammation is limited but 
promising, highlighting the importance of further research into the hormone’s anti-
inflammatory properties. 
 One option for research into FGF21 is the use of Fgf21 knock-out (Fgf21KO) 
mice in comparison to control wild-type (WT) mice. Fisher and colleagues sought to 
investigate similarities and differences between Fgf21KO and WT mice to establish that 
the two strains are phenotypically similar and comparisons between the two are valid.43 
While on chow-fed diets WT mice weighed less than Fgf21KO mice. Once put on a HFD 
that was intended to be obesogenic, the WT and Fgf21KO mice took on similar levels of 
adiposity. WT mice also experienced better glucose tolerance while on the chow diets, 
but these differences disappeared on the HFD. Circulating non-esterified fatty acids were 
also no longer different once the mice were put on the HFD. This research gives 
validation that WT and Fgf21KO mice can be appropriately compared when on a HFD.43 
 
 
 11 
 
Signal Transducer and Activator of Transcription 3 (STAT3) 
 The STATs are a set of transcription factors that are activated through the 
phosphorylation mediated by janus kinases (JAKs) and, once activated, dimerize, move 
to the nucleus, and affect gene transcription.30,50 Activators of the JAK-STAT pathway 
include cardiotrophin-1 (CT-1),51-53 growth hormone (GH),51,54 interferon gamma (IFN-
γ),51,55-57 interleukins 6 and 11 (IL-6 and IL-11),55,58,59 leukemia inhibitory factor 
(LIF),51,55,57,59,60 neuropoietin (NP),51,61-63 and oncostatin M (OSM).51,55,57,59,64 STAT3 is 
widely recognized for its role in propagating inflammation, but has been studied 
primarily for its role in cancer-related inflammation. Two phosphorylation sites have 
been identified on STAT3: Tyr705 and Ser727.50,65,66 The actions of and differences in 
phosphorylation sites are not completely understood. Phosphorylation at Tyr 705 appears 
to promote the dimerization of STAT3 and is essential for STAT3 activation,50,66,67 while 
phosphorylation at Ser727 seems to enhance the transcription effects of STAT3.50,66 
STAT3 is found in adipocytes68,69 and evidence suggests that phosphorylated STAT3 
(pSTAT3) plays a role in adipogenesis and preadipocyte differentiation.68,70-73 pSTAT3 
also upregulates the expression of pro-inflammatory markers.2,74 
 
MR and STAT3 
 Microarray analyses conducted on tissue samples from rats fed a control, MR, or 
40% calorie-restricted (CR) diet for 20 months showed that both MR and CR decreased 
expression of inflammatory genes in liver and WAT of rats.15 In fact, despite similar 
reductions in body weight and adiposity between the MR and CR rats, MR had a 
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significantly greater anti-inflammatory effect in liver and adipose tissue than CR. 
Furthermore, analysis using Ingenuity Pathway Analysis (Qiagen) software identified a 
downregulation of STAT3 signaling in liver and WAT of rats fed the MR diet.2 These 
data suggest that STAT3 may be the mechanism behind the MR-induced downregulation 
of age- and obesity-induced inflammation. 
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Chapter III 
Methods 
Animal Study 
 Animal studies were conducted at Pennington Biomedical Research Center, and 
tissues were generously provided by Dr. Tom Gettys. All animal experiments were 
reviewed and approved by the Pennington Institutional Animal Care and Use Committee 
using guidelines established by the National Research Council, the Animal Welfare Act, 
and the PHS Policy on humane care and use of laboratory animals. Male WT C57BL/6J 
mice were obtained from Jackson Labs (Bar Harbor, ME, USA), and Fgf21KO (KO) 
mice were kindly provided by Dr. Steve Kliewer (UT Southwestern). 24 WT C57BL/6J 
and 24 Fgf21KO mice, age 12 weeks, were fed a HFD for four weeks. After those four 
weeks, 12 WT and 12 KO mice were placed on high-fat methionine-restricted (MR) diets 
while the other mice remained on the control HFD (CON). The CON diet contained .86% 
methionine, by weight, and the MR diet contained .17% methionine and no cysteine (an 
80% reduction, typical for MR diets in mice). The WT and KO mice were fed the CON 
or MR diet for 13 weeks after randomization. After these 13 weeks, mice were 
euthanized and tissues were collected and flash frozen in liquid nitrogen.  
 
RNA Extraction and Real-time PCR 
 RNA was extracted from EWAT and liver samples using the Qiagen RNeasy 
Lipid Tissue Mini Kit 50. DNAse digestion was performed to improve purity of RNA. 
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RNA concentrations and purity were verified by nanodrop. From isolated RNA, reverse 
transcription was performed to make cDNA.  
 Real-time PCR (RT-PCR) using SYBR-green reagents was performed on Liver 
samples to measure expression of the inflammatory marker genes for Ccl2 (MCP-1) and 
Emr1 (F4/80) and on EWAT samples to measure expression of the inflammatory marker 
genes for Emr1 (F4/80), Itgam (CD11b), Il6 (interleukin-6), and Ccl2 (MCP-1). Gene 
expression measures were normalized to cyclophilin. 
Gene Forward Primer Reverse Primer 
Cyclophilin 5’-CTT CGA GCT GTT TGC 
AGA CAA AGT-3’ 
5’-AGA TGC CAG GAC CTG 
TAT GCT-3’ 
Ccl2 5’-GGA GAG ACA GCG GTC 
GTA AG-3’ 
5’-CCA GCC GGC AAC TGT 
GA-3’ 
Emr1 5’-GTG CCA TCA TTG CGG 
GAT TC-3’ 
5’-GAC GGT TGA GCA GAC 
AGT GA-3’ 
Itgam 5’-CCA CAC TAG CAT CAA 
GGG CA-3’ 
5’-CCC TGA TCA CCG TGG 
AGA AG-3’ 
Il6 5’-ATG GAT GCT ACC AAA 
CTG GAT-3’ 
5’-TGA AGG ACT CTG GCT 
TTG TCT-3’ 
Table 1. Forward and reverse primer sequences used in RT-PCR. 
 
Protein Extraction and Immunoblot Analysis 
 To determine if MR decreases inflammation through downregulation of STAT3 
signaling and to determine the role of FGF21 in anti-inflammatory effects of MR, 
western blot analyses of STAT3 phosphorylation at Tyr705 and Ser727 were conducted. 
Protein extracts from tissues were made by homogenizing ~100mg of each sample in 
300uL of radioimmunoprecipitation assay (RIPA) buffer containing protease and 
phosphatase inhibitors. Lysates were incubated in lysis buffer on ice for 20 minutes and 
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were then centrifuged for 30 minutes at 13,200 RPM at four degrees Celsius. The 
infranatant was collected and assayed for protein concentrations. Protein concentrations 
were determined by Lowry Protein assay. Protein samples were combined with laemmli 
buffer and boiled for five minutes. Protein from each sample were loaded onto a 10% 
Criterion Precast (Bio-Rad Laboratories) gel. Proteins were separated via electrophoresis 
at 90-110V for 2.5 hours. Proteins (total amounts varied between membranes) were 
transferred to a PVDF membrane overnight at 10V. Membranes were rinsed with 
deionized water the following day and were incubated in blocking buffer (5% BSA in 
TBSt) for 1 hour. Primary antibody (pSTAT3Tyr705 and pSTAT3Ser727 in 5% BSA and 
total STAT3 in 1% BSA) was added to a pouch with the membranes and incubated for 
either about one hour or overnight (varied by membrane and by antibody) at four degrees 
Celsius. Afterward, the membranes were washed in TBSt on a shaker for five minutes, 
three times. Secondary antibody was added to the membranes (anti-rabbit, in 1% BSA) 
and incubated for one hour, followed by another three washes in TBSt. The membrane 
was then covered with ECL for five minutes and immediately imaged using ImageQuant 
LAS4000 equipment and software (GE Healthcare). pSTAT3Tyr705 and pSTAT3Tyr705 
antibody from Cell Signaling Technology (Danvers, MA) were used; STAT3 antibody 
was from Santa Cruz Biotechnology (Santa Cruz, CA). Band densities of pSTAT3 were 
quantified using ImageJ software and normalized to total STAT3. 
 
Statistical Analysis 
 RT-PCR data were analyzed by one-way ANOVA. Tukey’s multiple comparisons 
test was used to identify significant differences between groups. Western blot data were 
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analyzed by unpaired t-test. Data was analyzed by Prism software (version 7.00, 
GraphPad, La Jolla, California). 
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Chapter IV 
Results 
Liver expression of MCP-1 and F4/80 
 KOCON mice had significantly increased expression of the inflammatory 
chemokine Ccl2 (MCP1) in the liver compared to WT mice (Fig. 1). MR decreased 
MCP-1 expression in KO mice (p<0.0001), and tended to do so in WT mice. However, 
WT mice fed the Con diet had significantly less MCP-1 expression in their liver 
compared to KO mice. Expression of the inflammatory macrophage marker, F4/80 
expression was unaffected by diet and genotype (Fig. 2). 
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Figure 1. Hepatic Ccl2 (MCP1) mRNA expression in WT and Fgf21KO mice. Values 
are means ± SEM, n=7-10. 
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Figure 2. Hepatic Emr1 (F4/80) mRNA expression in WT and Fgf21KO mice. Values 
are means ± SEM, n=6-9. 
 
MR decreased EWAT MCP-1 expression in both WT and Fgf21KO mice 
 MR decreased MCP-1 expression in EWAT of WT and Fgf21KO mice. No 
significant differences in EWAT MCP-1 mRNA expression were found between 
genotypes (Fig. 3). 
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Figure 3. EWAT Ccl2 mRNA expression in WT and Fgf21KO mice. Values are means ± 
SEM, n=8-10. 
 
MR decreased EWAT F4/80 expression in Fgf21KO mice 
 Fgf21KO mice had elevated Emr1 (F4/80) expression in EWAT compared to WT 
mice, and MR decreased its expression in Fgf21KO mice, but not in WT mice (Fig. 4). 
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Figure 4. EWAT Emr1 mRNA expression in WT and Fgf21KO mice. Values are means 
± SEM, n=8-10. 
 
EWAT Itgam and Il6 expression did not differ between groups 
 mRNA expression of Itgam, an inflammatory macrophage marker, in EWAT was 
similar between all four groups (Fig. 5). Additionally, mRNA expression of the 
inflammatory cytokine Il6 in EWAT was similar between all four groups of mice. 
Though trends seen in the figures are similar to those of Ccl2 and Emr1, differences 
between groups were not statistically significant (Fig. 6). 
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Figure 5. EWAT Itgam mRNA expression in WT and Fgf21KO mice. Values are means 
± SEM, n=5-9. 
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Figure 6. EWAT IL-6 mRNA expression in WT and Fgf21KO mice. Values are means ± 
SEM, n=8-9. 
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EWAT pSTAT3Tyr705, but not pSTAT3Ser727, was reduced by MR in WT mice 
 Since STAT3 is a transcription factor known to propagate inflammation and 
microarray analyses identified STAT3 as a potential master regulator of the anti-
inflammatory effects of MR, STAT3 phosphorylation in EWAT was measured. Western 
blot analyses of EWAT indicated that MR significantly decreased phosphorylation of 
STAT3 at Tyr705 in WT mice (p=0.0118) (Fig. 7). The analyses also showed no 
significant differences in phosphorylation of STAT3 at Ser727 between the two groups 
(Fig. 7).  
 
Figure 7. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in WTCON and WTMR mice. Values 
are means ± SEM, n=6. 
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EWAT pSTAT3Tyr705, but not pSTAT3Ser727, was significantly reduced by MR in Fgf21KO 
mice 
 Similarly to the WT mice, MR decreased phosphorylation of STAT3 at Tyr705 in 
the Fgf21KO mice (p=0.009) (Fig. 8). However, phosphorylation of STAT3 at Ser727 
was not significantly different between the two groups (Fig. 8). 
 
Figure 8. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in KOCON and KOMR mice. Values 
are means ± SEM, n=6. 
 
EWAT pSTAT3Tyr705 was affected by absence of FGF21 while pSTAT3Ser727 was not 
  WTCON and KOCON were compared to assess the effects that absence of Fgf21 
has on STAT3. Western blot analyses indicated that phosphorylation of STAT3 at 
Tyr705 was increased in Fgf21KO mice compared to WT mice (p=0.0177) (Fig. 9). 
Phosphorylation of STAT3 at Ser727, however, was not significantly different between 
WTCON and KOCON (Fig. 9). 
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Figure 9. EWAT pSTAT3Tyr705 and pSTAT3Ser727 in WTCON and KOCON mice. Values 
are means ± SEM, n=6. 
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Chapter V 
Discussion 
 Obesity increases inflammation throughout the body.1 This inflammation is 
characterized by increased inflammatory cytokine expression and increased ROS 
production, similar to inflammation observed in aging. 2,3 Inflammatory markers often 
upregulated in obesity include MCP-1, IL-1β, TNF-α, IL-6, IFN-γ, F4/80, ITGAM, and 
ITGAX. 15 
 NF-κB, a proinflammatory transcription factor, is activated by hypoxia in 
adipocytes and AT macrophages. This hypoxia response is initiated by adipocyte 
hypertrophy.1,75 Activation of this transcription factor is to blame for the upregulation of 
many pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and MCP-1.1,14,75 In 
addition to NF-κB activation, polarization of macrophages to the M1 type causes 
upregulation of pro-inflammatory cytokines.4,10,13  
 CR has gained attention for its ability to increase lifespan and adiposity in 
rodents.25 However, use of this dietary approach is not ideal for humans.2 MR has been 
shown to produce similar benefits as CR,27-30 but, interestingly, induces a hyperphagic 
response with simultaneous increased energy expenditure.27-29,35,37 MR also increases 
insulin sensitivity and decreases pro-inflammatory cytokine expression, reduces hepatic 
lipid stores, and reduces serum lipid levels.15,28,29,31,35 In the present study, both WTMR 
and KOMR mice weighed less than the CON groups. This reduction in weight was 
accompanied by a reduction in adiposity in WTMR and KOMR. Food intake increased in 
WTMR mice in comparison to WTCON, however KOMR mice did not develop a 
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hyperphagic response in comparison to KOCON (unpublished data from Gettys and 
colleagues). 
MR has been shown to decrease the pro-inflammatory cytokines MCP-1, IL-1β, 
TNF-α, IFN-γ, F4/80, ITGAM, and ITGAX in WAT and liver.15 In the present study, 
measures for MCP-1 and F4/80 in the liver and MCP-1, F4/80, ITGAM, and IL-6 in 
EWAT were gathered. Our data for MCP-1 were in agreement with other data that 
suggests downregulation of the gene in EWAT and liver of mice on dietary MR. EWAT 
F4/80, ITGAM, and IL6 were not in agreement with other data, but the data were 
trending toward downregulation of these pro-inflammatory genes in MR. A flaw of our 
study and similar studies is that only portions of each tissue from each mouse is taken and 
used for RNA isolation and subsequent reverse transcription and RT-PCR. Fluctuations 
of gene expression in various portions of the same tissue are common. Because we can 
only feasibly take a portion of each tissue, gene expression levels may be slightly 
different from total tissue gene expression. This may be why we found trends between 
groups without significant differences. Additionally, increasing the number of samples 
used in the study could help determine significance by limiting the SEM. 
 FGF21 is a hormone that increases glucose uptake by adipocytes, prevents 
obesity, decreases blood glucose, and decreases triglyceride levels.39 Studies show that 
MR increases levels of FGF21 in circulation.28,36-38 Inflammation (specifically, the 
presence of TNF-α) decreases FGF21 signaling in adipocytes through the reduced 
expression in co-receptor βKlotho.46 FGF21 serum levels are higher in obese rodents and 
humans, possibly as a result of FGF21 resistance. Exogenous administration, however, 
has been shown to improve weight in obese rodents and decrease pro-inflammatory 
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cytokine expression in the spleen of arthritic mice, suggesting its potential use as a 
pharmacologic agent.44,48,49 Additionally, recombinant FGF21 reduced expression of pro-
inflammatory cytokines in mouse WAT.47 Our data showed increased expression of Liver 
MCP-1 and EWAT F4/80 in KOCON mice when compared to all other groups. This 
suggests the Fgf21KO mice were more susceptible to HFD-induced inflammation. 
Western blot analyses showed increased phosphorylation of STAT3 at Tyr705 in 
KOCON when compared to WTCON. This suggests that the increased inflammation seen 
in the absence of FGF21 is potentially mediated by the phosphorylation of STAT3 at 
Tyr705. 
 STAT3, a generally pro-inflammatory transcription factor, is activated at two 
phosphorylation sites: Tyr705 and Ser727.50,65,66 Our data indicate that phosphorylation 
of STAT3 at Tyr705 is downregulated by MR in both WT and KO mice. Additionally, 
phosphorylation of STAT3 at Tyr705 is upregulated in KOCON mice when compared to 
WTCON mice. These data suggest that the mechanism by which MR downregulates 
phosphorylation of STAT3 at Ser727 is independent of Fgf21. Phosphorylation of 
STAT3 at Ser727 was unaffected by both MR and lack of FGF21. However, Tyr705 is 
the main site of phosphorylation on STAT3 while Ser727 is the secondary maximal 
activation site. The data which show downregulation of phosphorylated STAT3 at 
Tyr705 are in agreement with our hypothesis that STAT3 is a potential master regulator 
of inflammation in MR. 
In conclusion, MR decreased inflammation in both WT and Fgf21KO mice, 
indicating that Fgf21 does not play a role in the mechanisms by which MR reduces 
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inflammation. Western blot results support the hypothesis that MR decreases 
inflammation by downregulation of STAT3 signaling. 
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